Skip to content

Nasdaq · CIK 0001936258

NAMS NewAmsterdam Pharma Co N.V.

Insider trading from SEC Form 4. Last filing 10 d ago. Close $21.58 on Oct 9, 2026, +2% from the 52-week low and -48% from the high.

Last 90 days

Net insider value
-$1.1M
more sold than bought
Buys
1
$227k by 1 insider
Sells
2
$1.3M by 2 insiders
Insiders on file
11
with a Form 4 at this company

Price and insider trades, last year

NAMSOct 9, 2026 · close 21.58

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at NewAmsterdam Pharma Co N.V., scored.

ScoreInsiderValueHoldingsPrice contextFiled
15WeakJohannes Jacob Pieter Kastelein
Chief Scientific Officer
sell
$1.3M
50,246 shares
-42%+15% from low-41% from high
38WeakMichael H. Davidson
Chief Executive Officer
buy
$227k
10,000 shares
+1%-
26WeakJohn W Smither
director
sell
$41k
1,600 shares
-15%-
45ModerateLouise Frederika Kooij
Chief Accounting Officer
sell
$3.1M
150,000 shares
-91%-
14WeakForGrowth NAP B.V.
owner
sell
$762k
29,846 shares
-0%-
17WeakForGrowth NAP B.V.
owner
sell
$1.9M
74,910 shares
-1%-
17WeakForGrowth NAP B.V.
owner
sell
$2.3M
91,068 shares
-1%-
17WeakForGrowth NAP B.V.
owner
sell
$4.1M
157,234 shares
-1%-
17WeakForGrowth NAP B.V.
owner
sell
$3.0M
115,480 shares
-1%-
17WeakForGrowth NAP B.V.
owner
sell
$4.9M
191,762 shares
-2%-
17WeakForGrowth NAP B.V.
owner
sell
$12M
462,288 shares
-4%-
17WeakForGrowth NAP B.V.
owner
sell
$1.0M
41,803 shares
-0%-
5WeakForGrowth NAP B.V.
owner
sell
$273k
10,898 shares
-0%-

Transactions

The last 99 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 30, 2026Johannes Jacob Pieter Kastelein
Chief Scientific Officer
MOption exercise
Ordinary Sharesindirect: See footnotes10b5-1
+50,246--119,54810 d ago
Sep 30, 2026Johannes Jacob Pieter Kastelein
Chief Scientific Officer
SOpen-market sale
Ordinary Sharesindirect: See footnotes10b5-1
-50,246$25.03$1.3M69,30210 d ago
Sep 30, 2026Johannes Jacob Pieter Kastelein
Chief Scientific Officer
MOption exercise
Option (right to buy)derivativeindirect: See footnote10b5-1
-50,246$0.00$0344,98310 d ago
Sep 14, 2026Michael H. Davidson
Chief Executive Officer
POpen-market purchase
Ordinary Shares
+10,000$22.65$227k792,92327 d ago
Sep 4, 2026John W Smither
director
SOpen-market sale
Ordinary Shares
-1,600$25.32$41k8,76033 d ago
Sep 1, 2026Robert William Gunning
Vice President, Controller
AGrant or award
Ordinary Shares
+3,200$0.00$03,20039 d ago
Sep 1, 2026Robert William Gunning
Vice President, Controller
AGrant or award
Option (right to buy)derivative
+14,000$0.00$014,00039 d ago
May 1, 2025Juliette Berangere Audet
See Remarks
AGrant or award
Option (right to buy)derivative
+30,000$0.00$030,000May 2, 2025
Mar 26, 2025Louis G Lange
director
MOption exercise
Ordinary Shares
+3,102$0.00$010,062Mar 28, 2025
Mar 26, 2025Louise Frederika Kooij
Chief Accounting Officer
MOption exercise
Ordinary Shares
+8,269$0.00$023,269Mar 28, 2025
Mar 26, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Ordinary Shares
+16,539$0.00$060,539Mar 28, 2025
Mar 26, 2025Johannes Jacob Pieter Kastelein
Chief Scientific Officer
AGrant or award
Ordinary Sharesindirect: See footnote
+19,302$0.00$0169,302Mar 28, 2025
Mar 26, 2025Michael H. Davidson
Chief Executive Officer
AGrant or award
Ordinary Shares
+30,992$0.00$0364,305Mar 28, 2025
Mar 26, 2025Johannes Jacob Pieter Kastelein
Chief Scientific Officer
MOption exercise
Ordinary Shares
+45,481$0.00$079,481Mar 28, 2025
Mar 26, 2025Louis G Lange
director
AGrant or award
Restricted Stock Unitderivative
+3,308--3,308Mar 28, 2025
Mar 26, 2025Douglas F Kling
Chief Operating Officer
SOpen-market sale
Ordinary Shares
-16,539--44,000Mar 28, 2025
Mar 26, 2025Michael H. Davidson
Chief Executive Officer
MOption exercise
Ordinary Shares
+38,394$0.00$0402,699Mar 28, 2025
Mar 26, 2025Louise Frederika Kooij
Chief Accounting Officer
AGrant or award
Restricted Stock Unitderivative
+8,269--8,269Mar 28, 2025
Mar 26, 2025Louis G Lange
director
MOption exercise
Restricted Stock Unitderivative
-3,102--206Mar 28, 2025
Mar 26, 2025Johannes Jacob Pieter Kastelein
Chief Scientific Officer
AGrant or award
Restricted Stock Unitderivative
+45,481--45,481Mar 28, 2025
Mar 26, 2025Michael H. Davidson
Chief Executive Officer
SOpen-market sale
Ordinary Shares
-12,258--390,441Mar 28, 2025
Mar 26, 2025Douglas F Kling
Chief Operating Officer
AGrant or award
Restricted Stock Unitderivative
+16,539--16,539Mar 28, 2025
Mar 26, 2025Louise Frederika Kooij
Chief Accounting Officer
MOption exercise
Restricted Stock Unitderivative
-8,269--0Mar 28, 2025
Mar 26, 2025Michael H. Davidson
Chief Executive Officer
AGrant or award
Restricted Stock Unitderivative
+38,394--38,394Mar 28, 2025
Mar 26, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Restricted Stock Unitderivative
-16,539--0Mar 28, 2025
Mar 26, 2025Johannes Jacob Pieter Kastelein
Chief Scientific Officer
MOption exercise
Restricted Stock Unitderivative
-45,481--0Mar 28, 2025
Mar 26, 2025Michael H. Davidson
Chief Executive Officer
MOption exercise
Restricted Stock Unitderivative
-38,394--0Mar 28, 2025
Mar 24, 2025Johannes Jacob Pieter Kastelein
Chief Scientific Officer
MOption exercise
Ordinary Sharesindirect: See footnote
+150,000--150,000Mar 26, 2025
Mar 24, 2025Johannes Jacob Pieter Kastelein
Chief Scientific Officer
MOption exercise
Option (right to buy)derivativeindirect: See footnote
-150,000$0.00$0820,229Mar 26, 2025
Mar 17, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Ordinary Shares10b5-1
+88,112--132,112Mar 19, 2025
Mar 17, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Ordinary Shares10b5-1
+11,888$10.00$119k144,000Mar 19, 2025
Mar 17, 2025Douglas F Kling
Chief Operating Officer
SOpen-market sale
Ordinary Shares10b5-1
-100,000--44,000Mar 19, 2025
Mar 17, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Option (right to buy)derivative10b5-1
-88,112$0.00$047,251Mar 19, 2025
Mar 17, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Option (right to buy)derivative10b5-1
-11,888$0.00$0650,930Mar 19, 2025
Mar 4, 2025Louise Frederika Kooij
Chief Accounting Officer
MOption exercise
Ordinary Shares
+150,000--165,000Mar 5, 2025
Mar 4, 2025Louise Frederika Kooij
Chief Accounting Officer
SOpen-market sale
Ordinary Shares
-150,000$20.37$3.1M15,000Mar 5, 2025
Mar 4, 2025Louise Frederika Kooij
Chief Accounting Officer
MOption exercise
Option (right to buy)derivative
-150,000$0.00$018,073Mar 5, 2025
Feb 18, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Ordinary Shares10b5-1
+90,782--134,782Feb 20, 2025
Feb 18, 2025Douglas F Kling
Chief Operating Officer
SOpen-market sale
Ordinary Shares10b5-1
-90,782--44,000Feb 20, 2025
Feb 19, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Ordinary Shares10b5-1
+9,218--53,218Feb 20, 2025
Feb 19, 2025Douglas F Kling
Chief Operating Officer
SOpen-market sale
Ordinary Shares10b5-1
-9,218--44,000Feb 20, 2025
Feb 18, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Option (right to buy)derivative10b5-1
-90,782$0.00$0135,363Feb 20, 2025
Feb 19, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Option (right to buy)derivative10b5-1
-9,218$0.00$0126,145Feb 20, 2025
Jan 29, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Ordinary Shares10b5-1
+56,863--100,863Jan 31, 2025
Jan 29, 2025Douglas F Kling
Chief Operating Officer
SOpen-market sale
Ordinary Shares10b5-1
-56,863--44,000Jan 31, 2025
Jan 30, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Ordinary Shares10b5-1
+13,578--57,578Jan 31, 2025
Jan 30, 2025Douglas F Kling
Chief Operating Officer
SOpen-market sale
Ordinary Shares10b5-1
-4,664--52,914Jan 31, 2025
Jan 30, 2025Douglas F Kling
Chief Operating Officer
SOpen-market sale
Ordinary Shares10b5-1
-8,914--44,000Jan 31, 2025
Jan 29, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Option (right to buy)derivative10b5-1
-56,863$0.00$0239,723Jan 31, 2025
Jan 30, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Option (right to buy)derivative10b5-1
-13,578$0.00$0226,145Jan 31, 2025
Jan 27, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Ordinary Shares10b5-1
+104,174--148,174Jan 29, 2025
Jan 27, 2025Douglas F Kling
Chief Operating Officer
SOpen-market sale
Ordinary Shares10b5-1
-80,359--67,815Jan 29, 2025
Jan 27, 2025Douglas F Kling
Chief Operating Officer
SOpen-market sale
Ordinary Shares10b5-1
-23,815--44,000Jan 29, 2025
Jan 28, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Ordinary Shares10b5-1
+25,385--69,385Jan 29, 2025
Jan 28, 2025Douglas F Kling
Chief Operating Officer
SOpen-market sale
Ordinary Shares10b5-1
-20,237--49,148Jan 29, 2025
Jan 28, 2025Douglas F Kling
Chief Operating Officer
SOpen-market sale
Ordinary Shares10b5-1
-5,148--44,000Jan 29, 2025
Jan 27, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Option (right to buy)derivative10b5-1
-104,174$0.00$0321,971Jan 29, 2025
Jan 28, 2025Douglas F Kling
Chief Operating Officer
MOption exercise
Option (right to buy)derivative10b5-1
-25,385$0.00$0296,586Jan 29, 2025
Jan 7, 2025Louis G Lange
director
AGrant or award
Ordinary Shares
+6,960--6,960Jan 8, 2025
Jan 6, 2025Louis G Lange
director
AGrant or award
Option (right to buy)derivative
+32,500$0.00$032,500Jan 8, 2025
Jan 7, 2025Michael H. Davidson
Chief Executive Officer
AGrant or award
Ordinary Shares
+123,529--123,529Jan 7, 2025
Jan 7, 2025William A Jones Jr
Chief Commercial Officer
AGrant or award
Ordinary Shares
+43,000--43,000Jan 7, 2025
Jan 7, 2025Johannes Jacob Pieter Kastelein
Chief Scientific Officer
AGrant or award
Ordinary Shares
+34,000--34,000Jan 7, 2025
Jan 7, 2025Douglas F Kling
Chief Operating Officer
AGrant or award
Ordinary Shares
+44,000--44,000Jan 7, 2025
Jan 7, 2025Louise Frederika Kooij
Chief Accounting Officer
AGrant or award
Ordinary Shares
+15,000--15,000Jan 7, 2025
Jan 7, 2025Juliette Berangere Audet
Chief Business Officer
AGrant or award
Ordinary Shares
+14,000--15,104Jan 7, 2025
Jan 6, 2025Michael H. Davidson
Chief Executive Officer
AGrant or award
Option (right to buy)derivative
+670,467$0.00$0670,467Jan 7, 2025
Jan 2, 2025Juliette Berangere Audet
Chief Business Officer
AGrant or award
Option (right to buy)derivative
+100,000$0.00$0100,000Jan 6, 2025
Jan 2, 2025William A Jones Jr
Chief Commercial Officer
AGrant or award
Option (right to buy)derivative
+200,000$0.00$0200,000Jan 6, 2025
Jan 2, 2025Johannes Jacob Pieter Kastelein
Chief Scientific Officer
AGrant or award
Option (right to buy)derivative
+200,000$0.00$0200,000Jan 6, 2025
Jan 2, 2025Douglas F Kling
Chief Operating Officer
AGrant or award
Option (right to buy)derivative
+250,000$0.00$0250,000Jan 6, 2025
Jan 2, 2025Louise Frederika Kooij
Chief Accounting Officer
AGrant or award
Option (right to buy)derivative
+80,000$0.00$080,000Jan 6, 2025
Dec 30, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-29,846$25.54$762k10,656,172Jan 2, 2025
Dec 26, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-33,438$26.01$870k10,727,490Dec 30, 2024
Dec 27, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-41,472$25.95$1.1M10,686,018Dec 30, 2024
Dec 20, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-44,143$25.53$1.1M10,807,853Dec 26, 2024
Dec 20, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-5,629$26.13$147k10,802,224Dec 26, 2024
Dec 23, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-25,132$25.49$641k10,777,092Dec 26, 2024
Dec 24, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-16,164$25.66$415k10,760,928Dec 26, 2024
Dec 18, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-54,518$25.72$1.4M10,954,712Dec 20, 2024
Dec 18, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-46,210$26.55$1.2M10,908,502Dec 20, 2024
Dec 19, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-56,506$25.45$1.4M10,851,996Dec 20, 2024
Dec 16, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-1,096$25.00$27k11,123,614Dec 18, 2024
Dec 17, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-66,648$25.60$1.7M11,056,966Dec 18, 2024
Dec 17, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-47,736$26.45$1.3M11,009,230Dec 18, 2024
Dec 13, 2024Bain Capital Life Sciences Investors, LLC
owner
POpen-market purchase
Pre-Funded Warrant (right to buy)derivativeindirect: See footnotes
+1,632,653$24.50$40M1,632,653Dec 17, 2024
Dec 12, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-140,048$25.25$3.5M11,176,424Dec 16, 2024
Dec 12, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-25,963$26.18$680k11,150,461Dec 16, 2024
Dec 13, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-25,751$25.01$644k11,124,710Dec 16, 2024
Dec 10, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-259,739$25.22$6.6M11,519,021Dec 12, 2024
Dec 10, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-48,511$26.15$1.3M11,470,510Dec 12, 2024
Dec 11, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-130,561$25.26$3.3M11,339,949Dec 12, 2024
Dec 11, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-18,583$26.41$491k11,321,366Dec 12, 2024
Dec 11, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-4,894$27.11$133k11,316,472Dec 12, 2024
Nov 15, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-8,530$25.02$213k11,812,033Nov 19, 2024
Nov 18, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-33,273$25.08$834k11,778,760Nov 19, 2024
Nov 13, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-1,066$25.00$27k11,830,395Nov 15, 2024
Nov 14, 2024ForGrowth NAP B.V.
owner
SOpen-market sale
Ordinary Sharesindirect: See footnote10b5-1
-9,832$25.01$246k11,820,563Nov 15, 2024
Oct 9, 2024Michael H. Davidson
Chief Executive Officer
GGift
Warrant (right to buy)derivative
-15,000$11.50$173k85,000Oct 11, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

NAMS insider trading: NewAmsterdam Pharma Co N.V. | InsiderTell